Jefferies initiated coverage of Abivax (ABVX) with a Buy rating and $160 price target The firm views the company’s obefazimod as “differentiated” drug for ulcerative colitis. Abivax’s maintenance readout in Q2 is “fairly de-risked” and should provide clear path to approval, the analyst tells investors in a research note. Jefferies is also more bullish on the company’s potential in Crohn’s relative to buy-side expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Midday Fly By: Dick’s Sporting, Dollar General report quarterly beats
- Abivax gives up gains after denying report of Astra exclusivity
- Abivax says ‘we deny the rumors’ to Bloomberg after takeover report
- Abivax moves lower after denying La Lettre report
- Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca